StockNews.AISignal intelligence
Haemonetics Corporation · NYSE · Healthcare
Browse public HAE signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Haemonetics Corporation's recent third-quarter earnings report has surpassed expectations, showing a strong performance that could enhance investor confidence. This positive result is expected to lead to increased interest in HAE shares in the near term.
View signal analysisHAE trades at $80.53, 7.6% below its yearly peak. Price proximity to the 52-week high signals potential bullish movement.
View signal analysisHAE reported Q1 earnings of $1.10, beating estimates. Quarterly sales reached $321.394 million, exceeding expectations. FY2026 EPS guidance reaffirmed between $4.70 and $5.00. JP Morgan downgraded HAE from Overweight to Neutral. Other analysts maintained rating but lowered price targets.
View signal analysisHaemonetics has an RSI value of 25.47, indicating oversold conditions. The stock is down 19% over the past month, indicating a bearish trend. Haemonetics posted better-than-expected quarterly earnings on Aug. 8. Current share price is $73.99, near its 52-week low of $70.74. Investment opportunity exists due to the oversold status of HAE.
View signal analysis- Haemonetics acquires Attune Medical for $160 million, boosting the global Hospital business. - Attune Medical generated $22 million in revenue in fiscal 2023, expected accretive to Haemonetics. - Attune's ensoETM technology enhances Haemonetics' presence in electrophysiology market. - Transaction financed through cash and credit facility draw, expected to be completed in Q1 fiscal 2025. - The global electrophysiology devices market valued at $6.1 billion in 2022, expected to grow. Price Impact Rating: Bullish Impact Horizon Rating: Long-term Type: Corporate Developments
View signal analysis